Adalimumab
9 NDCs across 2 manufacturers|1 Generic,8 Brand
Adalimumab is used to treat juvenile arthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and hidradenitis suppurativa, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
In 2024, Medicare Part D spent $5.7 billion on Adalimumab across 652,000 claims for 90,000 beneficiaries.
Adalimumab is available as 9 NDCs from 2 manufacturers (1 generic, 8 brand), with NADAC prices from $872.72 to $6745.43 per EA — the most expensive product costs about 7.7× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
9
1G / 8B
Manufacturers
2
competing in market
Price Spread
$872.72 – $6745.43
per EA
7d Activity
avg -0.0% WoW · of 9 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
AbbVie Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
2 manufacturers producing ADALIMUMAB
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
HUMIRA(CF) PEN CROHN'S-UC-HS STARTER 80 MG/0.8 ML | $6745.4280 per EA | — |
HUMIRA(CF) PEN 80 MG/0.8 ML | $6736.7225 per EA | +0.04% |
HUMIRA(CF) PEN PS-UV-ADOL HS START 80 MG/0.8 ML-40 MG/0.4 ML | $4441.4694 per EA | — |
HUMIRA 40 MG/0.8 ML SYRINGE | $3369.0926 per EA | -0.07% |
HUMIRA(CF) PEN 40 MG/0.4 ML | $3367.4148 per EA | +0.01% |
HUMIRA(CF) 40 MG/0.4 ML SYRINGE | $3367.1829 per EA | -0.03% |
HUMIRA PEN 40 MG/0.8 ML | $3366.8965 per EA | 0.00% |
HUMIRA(CF) 20 MG/0.2 ML SYRINGE | $3366.1230 per EA | — |
ADALIMUMAB-AACF(CF) PEN 40 MG/0.8 ML (2 PACK) | $872.7167 per EA | -0.01% |
Frequently Asked Questions
What is Adalimumab used to treat?
Adalimumab is used to treat juvenile arthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and hidradenitis suppurativa, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Adalimumab?
In 2024, Medicare Part D spent $5.7 billion on Adalimumab across 652,000 claims for 90,000 beneficiaries.
How many Adalimumab products are on the market?
The Adalimumab drug market contains 9 NDCs from 2 manufacturers — 1 generic and 8 brand products.
What is the price range for Adalimumab?
NADAC reference prices for Adalimumab range from $872.7167 to $6745.4280 per EA — the most expensive product costs about 7.7× the cheapest.
Is generic Adalimumab cheaper than brand?
The average generic NADAC for Adalimumab is $872.7167 per EA, versus $4345.0412 for brand-labeled products — brand versions average about 5.0× the generic price.
Which manufacturers make Adalimumab?
2 manufacturers list Adalimumab in NADAC. Ranked by number of NDCs, the largest are AbbVie Inc. (8), Fresenius Kabi USA, LLC (1).
How has the price of Adalimumab changed recently?
Over the past 7 days, 2 Adalimumab NDCs rose and 3 fell, with a market-wide average change of -0.0%.